ORKA

Oruka Therapeutics, Inc.

NASDAQ: ORKA · HEALTHCARE · BIOTECHNOLOGY

$65.68

-3.44% today

Updated 2026-06-05

Market cap

$4.95B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.93

Dividend yield

—

52W range

$11 – $91

Volume

1.9M

Market cap

$4.95B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.93

Dividend yield

—

52W range

$11 – $91

Volume

1.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

16.5

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →205 stocks currently score above 75

Price targets

Analyst target

$142.17

+116.46%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Altman Z 16.52 — safe zone

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-23.65M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	—	—	—	$0.00	$0.00
Net income	$-9.93M	$-5.34M	$-83.72M	$-105.43M	$-31.82M
EPS	—	—	—	—	$-1.93
Free cash flow	$-18.80M	$-10.91M	$-58.03M	$-88.42M	$-23.65M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ORKA	$4.95B	25	4.3	3.0	5.0	8.0	—	Avoid
LLY	$1.08T	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$613.02B	57	4.7	9.0	3.3	6.0	-87.08%	Buy
ABBV	$447.62B	63	4.0	8.0	4.7	5.0	-73.27%	Buy
UNH	$388.59B	54	5.3	5.5	4.0	5.5	-33.19%	Buy
NVS	$296.54B	49	3.3	9.0	3.3	4.5	-69.70%	Hold

Smart narrative

Oruka Therapeutics, Inc. trades at $65.68. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 16.52, it sits in the safe zone.

Frequently asked questions

What is Oruka Therapeutics, Inc.'s stock price?

Oruka Therapeutics, Inc. (ORKA) trades at $65.68.

Is Oruka Therapeutics, Inc. overvalued?

Oruka Therapeutics, Inc. carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Oruka Therapeutics, Inc. (ORKA)?

The 12-month analyst consensus target is $142.17, about 116.5% above the current $65.68. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Oruka Therapeutics, Inc.'s Altman Z-Score is 16.52, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-23.89%

Beta—

50D MA$65.98

200D MA$39.72

Shares out0.06B

Float0.05B

Short ratio—

Avg volume1.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ORKA vs LLY →ORKA vs JNJ →ORKA vs ABBV →Stock screener →